Answers are grounded in this paper and cite their sources.
In vitro study shows near-infrared-activated indocyanine green enhances cisplatin-induced apoptosis in colorectal cancer cells, highlighting c-Fos signaling as a driver of therapeutic sensitivity.
Colorectal cancer (CRC) treatment remains limited by chemoresistance, highlighting the need for combination strategies that enhance therapeutic responses. Indocyanine green (ICG) is a clinically approved near-infrared (NIR)-responsive agent with photothermal and photodynamic properties. Here, we investigated the effects of NIR-activated ICG combined with cisplatin (CDDP) and the associated apoptotic mechanisms in HCT116 and HT29 CRC cells. NIR-activated ICG enhanced CDDP-induced cytotoxicity, with HCT116 cells exhibiting greater sensitivity than the more CDDP-resistant HT29 cells. Comparable intracellular ICG accumulation between the cell lines indicated that differential sensitivity was unlikely to result from differences in ICG uptake. RT-qPCR revealed preferential FOS induction in HCT116 cells, which was confirmed at the c-Fos protein level. Consistently, Annexin V/PI and cell-cycle analyses demonstrated greater apoptosis and sub-G1 accumulation in HCT116 cells. Combination treatment was further associated with reduced Bcl-2 and FBXL10 expression and increased caspase-3 and PARP cleavage. Collectively, these findings demonstrate that NIR-activated ICG potentiates CDDP-induced apoptosis and identify c-Fos-associated apoptotic signaling as a potential molecular determinant of treatment responsiveness in CRC cells.
No takes yet. Share an insight, caveat, or question.
Ho et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: